A common question I hear is whether hydroxyapatite is FDA approved. The short answer is no — not specifically for dental use. Below I explain what that means and what to look for when choosing a hydroxyapatite toothpaste or varnish.
Fluoride varnishes used in dental offices have FDA clearance as Class II medical devices, but that clearance relates to their use as cavity liners and desensitizers, not explicitly as caries-preventive agents. Clinicians often use fluoride varnish “off-label” for caries prevention, which the FDA permits when supported by professional judgment and evidence.
Hydroxyapatite does have FDA approvals for certain medical applications, but it is not currently approved by the FDA as an oral caries-preventive ingredient. In the U.S., the FDA does not allow cavity-fighting claims for toothpastes that do not contain fluoride. That regulatory constraint does not necessarily reflect the clinical effectiveness of hydroxyapatite; it reflects the current regulatory framework and available labeled indications.
Off-label use is common across medicine and dentistry. The FDA’s guidance makes clear that physicians and dentists may use legally available products for unapproved indications, provided they are well-informed, base their decisions on solid scientific rationale and evidence, and maintain records of use and outcomes. This approach underscores the importance of informed clinical judgment when adopting new materials or techniques.
Without a specific FDA approval for dental hydroxyapatite, what should consumers and clinicians look for when selecting a hydroxyapatite toothpaste or varnish? Here are practical quality criteria to consider.
1) Evidence of efficacy
Peer-reviewed clinical studies are the best source of evidence. Multiple peer-reviewed trials and reviews have reported benefits of hydroxyapatite for caries prevention, dentin sensitivity, and even whitening. Independent assessments, such as the Environmental Working Group (EWG), rate hydroxyapatite favorably, indicating low concern for environmental toxicity and bioaccumulation.
2) Systemic safety and manufacturing standards
Oral products affect more than just teeth, so systemic safety and manufacturing quality matter. The European Scientific Committee on Consumer Safety (SCCS) has evaluated nano-hydroxyapatite and concluded it is safe in oral cosmetic products at specific concentrations and particle characteristics: up to 10% in toothpaste and up to 0.465% in mouthwash, provided the particles meet defined size and shape criteria and are not surface-coated or modified. When manufacturers follow rigorous specifications and third-party testing standards, it increases confidence in product safety and consistency.
Will the FDA approve hydroxyapatite for dental use?
It’s possible. Regulatory and coding changes are already beginning to reflect growing acceptance. In 2024, new CDT codes were adopted for hydroxyapatite varnish application (D2991), describing per-tooth application limits and billing guidance. Such steps indicate progress toward wider clinical recognition, though adoption takes time as research, clinical practice, payers, and regulators align.
If you support broader recognition and coverage of hydroxyapatite products, consider contacting policymakers, insurance companies, and professional organizations. Clinicians who have observed positive outcomes often share data and letters advocating for coverage and acceptance. Below is an example of the type of professional letter that can be used to request insurance coverage or regulatory consideration for hydroxyapatite varnish.
Example letter urging insurance companies and/or FDA to consider hydroxyapatite varnish for coverage
Subject: Request for Coverage of Hydroxyapatite Varnish
Dear [Name],
I am writing to advocate for coverage of hydroxyapatite varnish under your dental insurance plans. As a pediatric dentist with extensive clinical experience, I have seen this material reduce the need for invasive restorations. Hydroxyapatite varnish provides a minimally invasive option to arrest and remineralize early lesions, often avoiding the need for local anesthesia, drilling, or sedation. This not only improves patient experience but also reduces overall treatment costs by preventing disease progression.
In my practice, hydroxyapatite varnish has reduced the number of fillings and anesthesia visits among children. It supports early intervention and can help maintain oral health with fewer invasive procedures. For these reasons, I recommend that you consider adding coverage for code D2991. I am available to provide research, clinical outcomes, or further information to support this request.
Sincerely,
[Clinician Name], [Credentials]
In summary: hydroxyapatite is not currently FDA-approved for caries prevention in the U.S., but it has supportive clinical evidence and favorable safety assessments from other regulatory bodies. Clinicians may use available evidence to make informed decisions, and ongoing regulatory and coding changes indicate growing acceptance. If you are a patient, ask your dental provider about the evidence and whether hydroxyapatite could be appropriate for your needs. If you are a clinician or advocate, consider sharing real-world outcomes and contacting payers and regulators to support broader recognition.
P.S. I regularly look for products that are independently tested for purity and safety. When choosing daily consumables like tea, which can impact overall health, I prefer brands that provide rigorous testing and transparency about contaminants and bioactivity.